Incretin hormones and type 2 diabetes

[1]  D. D’Alessio,et al.  Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction , 2022, Cardiovascular Diabetology.

[2]  M. Haluzík,et al.  The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia , 2022, Current Atherosclerosis Reports.

[3]  J. Holst.  Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture , 2021, Diabetes.

[4]  H. Grill,et al.  GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models , 2021, Diabetes.

[5]  A. Pfeiffer,et al.  The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update , 2021, Diabetes, obesity & metabolism.

[6]  Yuichiro Yamada,et al.  Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study , 2021, Journal of diabetes investigation.

[7]  J. Holst,et al.  Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects , 2021, Diabetes.

[8]  M. Tschöp,et al.  Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists , 2021, Molecular metabolism.

[9]  D. Drucker,et al.  Revisiting the complexity of GLP-1 action-from sites of synthesis to receptor activation. , 2020, Endocrine reviews.

[10]  Jonathan E. Campbell.  Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms , 2020, Molecular metabolism.

[11]  M. Nauck,et al.  GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art , 2020, Molecular metabolism.

[12]  A. Feuchtinger,et al.  The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling , 2020, Cell metabolism.

[13]  J. Holst,et al.  Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist , 2020, JCI insight.

[14]  M. Nauck,et al.  The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists , 2020, Diabetes, obesity & metabolism.

[15]  J. Holst,et al.  GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists , 2020, The Journal of clinical endocrinology and metabolism.

[16]  M. Coghlan,et al.  How May GIP Enhance the Therapeutic Efficacy of GLP-1? , 2020, Trends in Endocrinology & Metabolism.

[17]  J. Holst,et al.  GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. , 2020, The Journal of clinical endocrinology and metabolism.

[18]  G. Yeo,et al.  Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake , 2019, Cell metabolism.

[19]  J. Holst,et al.  Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists , 2019, Peptides.

[20]  Yuichiro Yamada,et al.  Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies For The Treatment Of Obesity, Do Agonists = Antagonists? , 2019, Endocrine reviews.

[21]  J. Holst,et al.  Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study , 2019, Diabetologia.

[22]  J. Holst,et al.  Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals , 2019, Diabetes.

[23]  D. Bates,et al.  Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models , 2018, Science Translational Medicine.

[24]  R. Hovorka,et al.  Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance , 2018, The Journal of clinical endocrinology and metabolism.

[25]  N. Lundbom,et al.  Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single‐centre randomized controlled study , 2018, Diabetes, obesity & metabolism.

[26]  G. Rutter,et al.  Targeting GLP-1 receptor trafficking to improve agonist efficacy , 2018, Nature Communications.

[27]  J. Holst,et al.  Preserved glucagon-like peptide-1 responses to oral glucose, but reduced incretin effect, insulin secretion and sensitivity in young Asians with type 2 diabetes mellitus , 2017, BMJ Open Diabetes Research and Care.

[28]  J. Holst,et al.  Glucagon‐like peptide‐1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men , 2017, Physiological reports.

[29]  D. D’Alessio,et al.  The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact? , 2016, American journal of physiology. Endocrinology and metabolism.

[30]  P. Rorsman,et al.  PYY-Dependent Restoration of Impaired Insulin and Glucagon Secretion in Type 2 Diabetes following Roux-En-Y Gastric Bypass Surgery , 2016, Cell reports.

[31]  A. Bjourson,et al.  Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice , 2016, Molecular and Cellular Endocrinology.

[32]  Liang Wang,et al.  Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis , 2015, Scientific Reports.

[33]  J. Rosenstock,et al.  Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial , 2015, Diabetes Care.

[34]  T. Hansen,et al.  GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study , 2015, Diabetes.

[35]  A. Droit,et al.  Effect of sitagliptin therapy on triglyceride‐rich lipoprotein kinetics in patients with type 2 diabetes , 2014, Diabetes, obesity & metabolism.

[36]  J. Holst,et al.  Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. , 2014, The Journal of clinical endocrinology and metabolism.

[37]  Sungwan Kim,et al.  The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes , 2014, Clinical endocrinology.

[38]  J. Holst,et al.  Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and “Isoglycemic” Intravenous Glucose , 2014, Diabetes.

[39]  Bin Yang,et al.  Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans , 2013, Science Translational Medicine.

[40]  J. Holst,et al.  Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes , 2013, Diabetes Care.

[41]  J. Holst,et al.  Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies , 2013, Diabetologia.

[42]  J. Holst,et al.  Glucose-Dependent Insulinotropic Polypeptide , 2011, Diabetes.

[43]  J. Holst,et al.  The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. , 2011, American journal of physiology. Endocrinology and metabolism.

[44]  J. Holst,et al.  Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans , 2011, Diabetes.

[45]  J. Holst,et al.  GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes , 2011, Diabetes.

[46]  Henrik Vestergaard,et al.  Impaired regulation of the incretin effect in patients with type 2 diabetes. , 2011, The Journal of clinical endocrinology and metabolism.

[47]  J. Holst,et al.  Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. , 2011, The Journal of clinical endocrinology and metabolism.

[48]  C. Deacon,et al.  Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review , 2011, Diabetes, obesity & metabolism.

[49]  M. Taskinen,et al.  One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. , 2010, Atherosclerosis.

[50]  J. Holst,et al.  The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action , 2010, Diabetes.

[51]  A. Astrup,et al.  On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans. , 2010, American journal of physiology. Endocrinology and metabolism.

[52]  D. Drucker,et al.  The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice , 2010, Diabetologia.

[53]  J. Holst,et al.  Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. , 2009, The Journal of clinical endocrinology and metabolism.

[54]  J. Egan,et al.  Exogenous Glucose–Dependent Insulinotropic Polypeptide Worsens Post prandial Hyperglycemia in T ype 2 Diabetes , 2009, Diabetes.

[55]  T. Vilsbøll,et al.  Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes , 2009, Diabetologia.

[56]  Andrea Mari,et al.  Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients , 2008, Diabetes.

[57]  J. Holst,et al.  Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes , 2008, Diabetologia.

[58]  Sten Madsbad,et al.  Reduced Incretin Effect in Type 2 Diabetes , 2007, Diabetes.

[59]  N. Irwin,et al.  Comparison of the subchronic antidiabetic effects of DPP IV–resistant GIP and GLP‐1 analogues in obese diabetic (ob/ob) mice , 2007, Journal of peptide science : an official publication of the European Peptide Society.

[60]  S. Bonner-Weir,et al.  Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia , 2007, Diabetes.

[61]  M. Taskinen,et al.  Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes , 2006, Diabetologia.

[62]  M. Feinglos,et al.  Effects of liraglutide (NN2211), a long‐acting GLP‐1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[63]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[64]  Jens J. Holst,et al.  Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes , 2004, Regulatory Peptides.

[65]  J. Holst,et al.  Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. , 2004, American journal of physiology. Endocrinology and metabolism.

[66]  J. Holst,et al.  Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[67]  J. Holst,et al.  Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia , 2003, Diabetologia.

[68]  J. Holst,et al.  The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. , 2003, Diabetes.

[69]  S. Kahn,et al.  The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes , 2003, Diabetologia.

[70]  R. Pederson,et al.  A novel pathway for regulation of glucose‐dependent insulinotropic polypeptide receptor expression in β‐cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[71]  J. Holst,et al.  Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients , 2002, Diabetologia.

[72]  Yuichiro Yamada,et al.  Inhibition of gastric inhibitory polypeptide signaling prevents obesity , 2002, Nature Medicine.

[73]  J. Holst,et al.  Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. , 2002, The Journal of clinical endocrinology and metabolism.

[74]  J. Holst,et al.  Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. , 2001, The Journal of clinical endocrinology and metabolism.

[75]  J. Holst,et al.  Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.

[76]  J. Holst,et al.  Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. , 2001, Diabetes.

[77]  J. Holst,et al.  Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. , 1998, Diabetes care.

[78]  P. Rorsman,et al.  Glucagon-Like Peptide I and Glucose-Dependent Insulinotropic Polypeptide Stimulate Ca2+-Induced Secretion in Rat α-Cells by a Protein Kinase A–Mediated Mechanism , 1997, Diabetes.

[79]  H. Vermeer,et al.  Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man , 1992, European journal of clinical investigation.

[80]  S. Ohashi,et al.  Reduced Insulinotropic Effects of Glucagonlike Peptide I-(7–36)-Amide and Gastric Inhibitory Polypeptide in Isolated Perfused Diabetic Rat Pancreas , 1990, Diabetes.

[81]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[82]  S. Madsbad,et al.  Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus. , 1987, Metabolism: clinical and experimental.

[83]  J. Holst,et al.  Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut , 1987, FEBS letters.

[84]  J. Brown,et al.  Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. , 1978, Endocrinology.

[85]  J. Brown,et al.  The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. , 1976, Endocrinology.

[86]  J. Brown,et al.  Stimulation of insulin secretion by gastric inhibitory polypeptide in man. , 1973, The Journal of clinical endocrinology and metabolism.

[87]  J. Holst,et al.  Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. , 1996, The Journal of clinical endocrinology and metabolism.

[88]  R. Jorde,et al.  Effect of intravenously infused porcine GIP on serum insulin in obese and lean subjects studied with the hyperglycemic clamp technique. , 1985, Scandinavian journal of gastroenterology.

[89]  R. Jorde,et al.  Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state. , 1985, Scandinavian journal of gastroenterology.